Study of tulisokibart for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a Crohn's disease diagnosis for at least 3 months.
- Your Crohn's disease is moderate to severe.
- You have tried other treatments like steroids, immunomodulators, or biologics without enough success or you couldn't tolerate them.
- You are 16 years old or older (teens 16-17 may join if local rules allow).
- You do not have certain complications like abscesses, strictures, or prior surgery that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.